Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-29T22:42:03.489Z Has data issue: false hasContentIssue false

Improvement in patient symptoms and functioning during long-term treatment with olanzapine long-acting injection (OLAI)

Published online by Cambridge University Press:  16 April 2020

J. Peuskens
Affiliation:
UPC K.U. Leuven, Kortenberg, Belgium
V. Porsdal
Affiliation:
Eli Lilly, Lyngby, Denmark
J. Pecenak
Affiliation:
Medical Faculty, Comenius University, Bratislava, Slovak Republic
P. Handest
Affiliation:
Psykiatrisk Center Hvidovre, Brøndby, Denmark
Y. D’yachkova
Affiliation:
Eli Lilly, Vienna, Austria
R. Brousil
Affiliation:
Eli Lilly, Praha, Czech Republic
M. Casillas
Affiliation:
Eli Lilly, Alcobendas, Spain
W. Deberdt
Affiliation:
Eli Lilly, Brussel, Belgium

Abstract

Introduction, objectives and aims

To evaluate the outcome of patients with schizophrenia during maintenance treatment with OLAI.

Methods

Data from three studies with OLAI were pooled and patients classified according to a cluster analysis [Lipkovich, Psychiatry Res, 2009] into five categories according severity of psychiatric symptoms (sx) and functional impairment (imp):

  1. A (minimal sx/mild imp),

  2. B (minimal sx/moderate imp),

  3. C (moderate sx/mild to moderate imp),

  4. D (moderate sx/severe imp),

  5. E (moderate to severe sx/severe imp).

Improvement was defined as a change from B or C to A, or from D or E to A, B or C. Changes between the categories in the 6 months were analyzed. Stepwise logistic regression modeling was done to determine factors associated with improvement.

Results

1182 patients were classified. Patients who remained in the studies at 6 months had lower baseline CGI-S (3.04 vs 3.28, p < 0.001), lower PANSS (61.38 vs 64.05, p = 0.012) and higher QLS (1.76 vs 1.39, p = 0.001). (Table 1) As patients in category A couldn’t improve and in category D&E couldn’t worsen, 261(39%) patients from categories B, C, D and E improved and only 55(10%) from categories A, B and C got worse during 6 months. Baseline factors associated with improvement were: baseline category (p < 0.001), CGI-S score (p = 0.022), and PANSS positive (p = 0.003)

Conclusions

Majority of patients with schizophrenia who stay on 6 months treatment with OLAI improve or maintain their symptoms and functioning level. The strongest factor associated with a higher chance of improvement was poor baseline category.

Type
P03-303
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.